(Observer Network News) On January 19, according to the "Guangdong Union Diclofenac and Other Drugs Centralized Procurement Document" issued by the Guangdong Provincial Drug Trading Center, blood products entered the scope of procurement for the first time, specifically involving five varieties of intravenous injection of human immunoglobulin (pH4), human immunoglobulin, human coagulation factor VIII., human fibrinogen, and human blood albumin. According to the aforementioned collection documents, recombinant human growth hormone was also included in the collection for the first time.
After the news was released, Hualan Bio once fell 7.7%, and as of press time, the decline was reduced to 6%. Hualan Bio is a company mainly engaged in the research and development, production and sales of blood products, vaccines and genetic engineering products, of which blood products create the company's main revenue. In addition, blood products companies such as Shanghai Laixi and Weiguang Biology have also fallen.
Hualan Bio 19th trend chart